Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
POLA1 | SNV | Missense_Mutation | | c.2978N>T | p.Thr993Met | p.T993M | | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-D8-A1JU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
POLA1 | SNV | Missense_Mutation | | c.1889C>T | p.Ala630Val | p.A630V | | protein_coding | tolerated(0.08) | possibly_damaging(0.649) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
POLA1 | insertion | Frame_Shift_Ins | novel | c.1609_1610insGATTCTTGATGATTAAATACAAGAGCATGTATTGTAAT | p.Asp537GlyfsTer22 | p.D537Gfs*22 | | protein_coding | | | TCGA-A2-A0EO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
POLA1 | insertion | Nonsense_Mutation | novel | c.3281_3282insAGTGCTGATATGATCTAGCCCCTGCTTGAAGCCTATATGTGAGTGTT | p.Lys1095ValfsTer4 | p.K1095Vfs*4 | | protein_coding | | | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD |
POLA1 | SNV | Missense_Mutation | novel | c.2001N>C | p.Lys667Asn | p.K667N | | protein_coding | deleterious(0) | probably_damaging(0.969) | TCGA-C5-A1M6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
POLA1 | SNV | Missense_Mutation | | c.2318A>G | p.Gln773Arg | p.Q773R | | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-EK-A2RN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
POLA1 | SNV | Missense_Mutation | | c.4272G>T | p.Lys1424Asn | p.K1424N | | protein_coding | tolerated(0.11) | benign(0.006) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
POLA1 | SNV | Missense_Mutation | | c.71N>G | p.Ser24Cys | p.S24C | | protein_coding | deleterious(0.01) | benign(0.121) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
POLA1 | SNV | Missense_Mutation | | c.1531N>G | p.Gln511Glu | p.Q511E | | protein_coding | tolerated(0.15) | benign(0.025) | TCGA-JW-A5VH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
POLA1 | SNV | Missense_Mutation | novel | c.3962N>T | p.Cys1321Phe | p.C1321F | | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-VS-A9V2-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5422 | POLA1 | DNA DIRECTED RNA POLYMERASE, DRUGGABLE GENOME, DNA REPAIR | | BROMOVINYL DEOXYURIDINE | | |
5422 | POLA1 | DNA DIRECTED RNA POLYMERASE, DRUGGABLE GENOME, DNA REPAIR | | FLUDARABINE | FLUDARABINE | |
5422 | POLA1 | DNA DIRECTED RNA POLYMERASE, DRUGGABLE GENOME, DNA REPAIR | | CLOFARABINE | CLOFARABINE | |
5422 | POLA1 | DNA DIRECTED RNA POLYMERASE, DRUGGABLE GENOME, DNA REPAIR | | CLOFARABINE | CLOFARABINE | |
5422 | POLA1 | DNA DIRECTED RNA POLYMERASE, DRUGGABLE GENOME, DNA REPAIR | | DIGALLIC ACID | DIGALLIC ACID | 1705574 |
5422 | POLA1 | DNA DIRECTED RNA POLYMERASE, DRUGGABLE GENOME, DNA REPAIR | | NELARABINE | NELARABINE | |
5422 | POLA1 | DNA DIRECTED RNA POLYMERASE, DRUGGABLE GENOME, DNA REPAIR | | FLUDARABINE | FLUDARABINE | |
5422 | POLA1 | DNA DIRECTED RNA POLYMERASE, DRUGGABLE GENOME, DNA REPAIR | inhibitor | CHEMBL803 | CYTARABINE | |
5422 | POLA1 | DNA DIRECTED RNA POLYMERASE, DRUGGABLE GENOME, DNA REPAIR | inhibitor | CHEMBL1750 | CLOFARABINE | |
5422 | POLA1 | DNA DIRECTED RNA POLYMERASE, DRUGGABLE GENOME, DNA REPAIR | inhibitor | CHEMBL1096882 | FLUDARABINE PHOSPHATE | |